ALIM Alimera Sciences Inc.

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Latest News

1. 06 August 2019 How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?
2. 05 August 2019 Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema
3. 03 August 2019 Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT
4. 29 July 2019 Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update
5. 23 July 2019 Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting
6. 22 July 2019 Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update
7. 19 July 2019 Alimera Sciences Announces the Appointment of Industry Veteran and Ophthalmology Business Executive John Snisarenko to its Board of Directors
8. 20 June 2019 Did Changing Sentiment Drive Alimera Sciences's (NASDAQ:ALIM) Share Price Down A Painful 85%?
9. 20 June 2019 Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis
10. 06 June 2019 Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment
11. 04 June 2019 Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
12. 22 May 2019 Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®
13. 21 May 2019 Top Ranked Momentum Stocks to Buy for May 21st
14. 14 May 2019 Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
15. 05 May 2019 Edited Transcript of ALIM earnings conference call or presentation 30-Apr-19 1:00pm GMT
16. 29 April 2019 Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview
17. 23 April 2019 Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update
18. 23 April 2019 Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
19. 04 April 2019 Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer
20. 25 March 2019 Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe